SCHEMBL3048738

SCHEMBL3048738

COc1cc2c(cc1O)CCN(S(=O)(=O)c1cccc(Cl)c1)C2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.64
PKM P14618 4/20 0.57
PDE4B Q07343 2/20 0.55
AKR1C1 Q04828 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CA7 P43166 1/20 0.52
LMNA P02545 1/20 0.52
ALDH1A1 P00352 1/20 0.51
ESR2 Q92731 1/20 0.50
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
PDE4D Q08499 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3059224 0.88 AKR1C3 (0.65) AKR1C3PKMPDE4BSMN1; SMN2CYP3A4
SCHEMBL3058872 0.88 AKR1C3 (0.65) AKR1C3PKMPDE4BSMN1; SMN2CYP3A4
SCHEMBL3062438 0.87 AKR1C3 (0.59) AKR1C3PKMPDE4BAKR1C1SMN1; SMN2
SCHEMBL3058949 0.84 AKR1C3 (0.60) AKR1C3PKMPDE4BSMN1; SMN2CYP3A4
SCHEMBL3059177 0.84 AKR1C3 (0.60) AKR1C3PKMPDE4BAKR1C1SMN1; SMN2
SCHEMBL3056631 0.83 AKR1C3 (0.58) AKR1C3PKMPDE4BSMN1; SMN2CYP3A4
SCHEMBL3061348 0.82 PKM (0.84) AKR1C3PKMPDE4BSMN1; SMN2CYP3A4
SCHEMBL3056417 0.82 AKR1C3 (0.60) AKR1C3PKMPDE4BAKR1C1SMN1; SMN2
SCHEMBL3062599 0.80 CA7 (0.56) AKR1C3PKMPDE4BSMN1; SMN2CYP3A4
SCHEMBL3051277 0.80 MMP2 (0.46) AKR1C3PDE4BCYP3A4NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC AKR1C3 1870/4885PKM 3021/4885PDE4B 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.